PPARD and metabolic dysfunction-associated steatohepatitis: The use of the PPARδ-selective agonist seladelpar (MBX-8025) for the treatment of NASH has been once discontinued at phase 2b [9], while that of the PPARα/δ dual agonist elafibranor against NASH has been discontinued due to its non-significant benefits [10].